Back to Journals » International Journal of Clinical Transfusion Medicine » Volume 4

Cryoprecipitate transfusion: current perspectives

Authors Wong H, Curry N

Received 30 May 2016

Accepted for publication 20 July 2016

Published 22 September 2016 Volume 2016:4 Pages 89—97

DOI https://doi.org/10.2147/IJCTM.S99042

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Cees Th. Smit Sibinga


Henna Wong, Nicola Curry

Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Abstract: Cryoprecipitate is prepared by controlled thawing of frozen plasma and is a rich source of fibrinogen, FVIII, von Willebrand factor, Factor XIII, and fibronectin. It is mainly transfused in Western countries as a concentrated source of fibrinogen replacement for acquired hypofibrinogenemia. During major bleeding, fibrinogen is the first clotting protein to be depleted to critically low levels. Increasing recognition of the importance of maintaining fibrinogen levels in bleeding has led to significant interest in appropriate fibrinogen supplementation. This review presents an overview of the indications, use and evidence for cryoprecipitate transfusion in hemorrhage, how it may promote hemostasis, and recent developments in extended thaw cryoprecipitate.

Keywords: cryoprecipitate, fibrinogen, hypofibrinogenemia, major hemorrhage, bleeding

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]